Medical/Pharmaceuticals
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to implant FDA-approved novel defibrillation lead
The new technology is the world's smallest, catheter-delivered defibrillation lead AUSTIN, Texas, Feb. 2, 2026 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an FDA-approved no...
2026-02-02 09:08
2944
International Cancer Organizations Work Together to Meet the Needs of Women with Cancer in Vietnam
The National Comprehensive Cancer Network (NCCN) is collaborating with the Vietnam National Cancer Hospital (K Hospital) to adapt regional recommendations for treating breast and ovarian cancers. HANOI, Vietnam, Feb. 2, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an a...
2026-02-02 09:08
2916
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Adult Type 2 Diabetes
HANGZHOU, China, Jan. 30, 2026 /PRNewswire/ -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has approved ...
2026-01-30 19:54
5534
Philips Receives Frost & Sullivan's 2025 Global Enabling Technology Leadership Recognition for Excellence in Digital Pathology-Healthcare Informatics
Philips is recognized for its market-leading innovation and comprehensive
digital pathology ecosystem, driving global transformation in diagnostics and
healthcare informatics
SAN ANTONIO, Jan. 30, 2026 /PRNewswire/ -- Frost & Sullivan
2026-01-30 02:00
4593
Zeus Launches PFX™ Platform and Introduces PFX Flex™ Sub-Lite-Wall™, Advancing the Future of Catheter Innovation
Polymer platform sets a new standard for catheter design with PTFE-like performance and expanded material flexibility ORANGEBURG, S.C., Jan. 29, 2026 /PRNewswire/ -- Zeus, a global leader in advanced polymer solutions, today announced the launch of PFX™, a breakthrough platform designed to advan...
2026-01-29 23:00
5090
Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao
BOAO, China, Jan. 29, 2026 /PRNewswire/ -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackle...
2026-01-29 20:00
3633
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial couple...
2026-01-29 19:00
4361
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
* Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family * Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology * SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine...
2026-01-29 10:10
4749
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imaging i...
2026-01-29 07:43
3718
REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools
BELTSVILLE, Md., Jan. 29, 2026 /PRNewswire/ -- REPROCELL today announced the commercial launch ofStemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveragingOpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEd...
2026-01-28 22:00
4589
NYSE Content Advisory: Pre-Market Update + First Lady Melania Trump to Ring NYSE Bell for Doc 'Melania'
NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + First Lady Melania Tr...
2026-01-28 21:55
6855
Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications
HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Con...
2026-01-28 19:39
3812
CHCC 2026 Opens Registration, Offering a One-Stop Platform for Hospital Construction Solutions and Real-World Applications
TIANJIN, China, Jan. 28, 2026 /PRNewswire/ -- The 27th China Hospital Construction Conference & International Hospital Build and Infrastructure Exposition (CHCC 2026), a globally recognized hospital construction event, will be held from May 23 to 25, 2026, at the National Convention and Exhibitio...
2026-01-28 15:01
4202
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from base...
2026-01-28 10:45
5206
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting. Skyhawk also ann...
2026-01-27 21:00
4388
Libevitug Approved in China as First-in-Class Hepatitis D Treatment
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a hum...
2026-01-27 16:15
4279
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
* Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. * Growth over the financial year was driven by increased sales in oncology, particularly in the United States. * Several partnership agreements in oncology and neurology strengthen the Group's R&D portfoli...
2026-01-27 16:00
3955
3Shape appoints Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy
COPENHAGEN, Denmark, Jan. 27, 2026 /PRNewswire/ -- 3Shape today announced the appointment of Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy, effective 9 March. Rasmus will step into the Senior Leadership Team and will report directly to CEO Jacob Paulsen. Rasmus joins 3S...
2026-01-27 15:45
3439
Getinge Q4 and Full-Year Report 2025: Organic growth and solid cash flow to end the year
GOTHENBURG, Sweden, Jan. 27, 2026 /PRNewswire/ -- "We succeeded in growing organically, delivering a record-breaking fourth quarter and organic growth at the upper end of our forecast, 4.9% for the full year," says Mattias Perjos, President & CEO at Getinge. Higher demand for consumables for ECL...
2026-01-27 15:23
3141
Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Prevention Initiative
DAVOS, Switzerland, Jan. 27, 2026 /PRNewswire/ -- At the 2026 World Economic Forum Annual Meeting in Davos, Dr. Giovanni Caforio, Chairman of the Board of Directors of Novartis, announced a major new partnership: the Novartis Foundation, the Ministry of Health of Brunei Darussalam, and EVYD Techn...
2026-01-27 14:37
5510
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 299 media titles]
2026-02-10 13:31Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
[Picked up by 299 media titles]
2026-02-09 10:00
Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 294 media titles]
2026-02-11 11:00
Vizzio Technologies Strengthens Leadership As Global Growth Accelerates
[Picked up by 293 media titles]
2026-02-11 14:59
Most Read
Angel Yeast Indonesia Project: Strengthening Foundations through Technical Training and Building Consensus through Cultural Exchange
2026-02-07 09:31
8059
DaVinci Gourmet Named Title Sponsor of The World's 100 Best Coffee Shops 2026, to Be Unveiled in Madrid
2026-02-06 21:28
7804
/C O R R E C T I O N -- Fairland Group - iGarden/
2026-02-08 17:31
7243
